Skip to content
Evigrade
MinorSodium-glucose cotransporter-2 (SGLT2) inhibitor×Gabapentinoids (antiepileptics)

Updated · Methodology

Mechanism

Gabapentin is not metabolised in the body and is excreted unchanged by the kidneys. Its clearance is directly proportional to creatinine clearance (gabapentin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Dapagliflozin is metabolised mainly by UGT1A9 to an inactive glucuronide that is excreted in the urine, and it neither inhibits nor induces cytochrome P450 enzymes (dapagliflozin SmPC, European Medicines Agency, EMA). In studies, dapagliflozin did not meaningfully inhibit the transporters P-glycoprotein (P-gp), OCT2, OAT1 and OAT3, and gabapentin did not inhibit the main cytochrome P450 enzymes (Farxiga and Neurontin labels, US Food and Drug Administration, FDA). The metabolic pathways of the two drugs do not overlap, and neither drug's documents name the other drug or its class.

Symptoms

The documents describe no symptoms linked to this combination. Gabapentin very commonly causes somnolence, dizziness and ataxia (gabapentin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Dapagliflozin increases urine output and can lower blood pressure slightly. Its common effects include dizziness and genital and urinary tract infections, and a rare serious complication is diabetic ketoacidosis, sometimes with blood glucose below 14 mmol/L (dapagliflozin SmPC, European Medicines Agency, EMA).

Management

According to the documents, the combination is acceptable, and the doses of gabapentin and dapagliflozin need no change. No document names the pair, and their elimination pathways do not overlap (gabapentin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; dapagliflozin SmPC, European Medicines Agency, EMA). The gabapentin dose is based on creatinine clearance and is reduced according to the SmPC table when creatinine clearance is below 79 mL/min (gabapentin SmPC, AEMPS). Before dapagliflozin starts, renal function and volume status are assessed, and volume depletion is corrected first (Farxiga label, US Food and Drug Administration, FDA). In illnesses that can lead to fluid loss, such as gastrointestinal illness, volume status is monitored closely, and if volume depletion develops, dapagliflozin is interrupted until it is corrected (dapagliflozin SmPC, EMA). People are advised not to drive until they know whether gabapentin affects their driving, because it causes somnolence and dizziness (Neurontin label, FDA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Dapagliflozin

Other interactions with Gabapentin